BioSpace News Archive

Assure Holdings Corp. (the “Company” or “Assure”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services, will hold a conference call on Tuesday, November 26, 2019, at 11:00 a.m. Eastern time to discuss its financial results for the third quarter ended September 30, 2019

Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced it will host an investor event to review the full safety, clinical efficacy, and biomarker data from Part 1 of the Phase 1/2 clinical trial of RP1 alone and in combination with Opdivo®

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics, provided a regulatory and clinical update on IDE196 following receipt of meeting minutes from an End‑of‑Phase 1 (EOP1) meeting with the FDA.

Medpace Holdings, Inc. announced that it will present at the following investor conference in November

Achieved target number of 22 clinical sites opened and recruiting patients in the U.S. and Belgium. Filed protocol amendment with the regulatory agencies in both countries to optimize the SARA-INT Phase 2b clinical trial

The amendment, which was filed with the FDA and AFMPS, proposes a reduction in the number of patients needed in SARA-INT based on fast deterioration of mobility seen in the SARA-OBS study in participants with sarcopenia

Centene Corporation (NYSE: CNC) announced today it will present at two healthcare conferences in November.

Fast-Growing Canadian Life Science Company adopts eTMF Connect to drive greater efficiency and visibility across clinical studies.

Revenue of $30.8 million, an increase of 33.8% year-over-year

Curis, Inc. announced that the Company will release its third quarter financial results on Tuesday, November 5, 2019, before the open of US markets.